Quantcast
Last updated on April 24, 2014 at 5:01 EDT

Latest Ustekinumab Stories

2014-03-24 08:28:42

Results from Phase 2b X-PLORE Study through Week 40 Report Efficacy of Guselkumab across Multiple Dosing Regimens and Compared with Adalimumab DENVER, March 24, 2014 /PRNewswire/ -- New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared or minimal at week 16, the...

2014-02-06 23:24:53

MarketResearchReports.Biz announces addition of new report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description” to its database. Visit: http://www.marketresearchreports.biz/analysis/186872 Albany, NY (PRWEB) February 06, 2014 Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description Research...

2013-12-05 08:27:49

Seventy-Two Percent of Surveyed Dermatologists Expect to Prescribe Apremilast if the Drug is Placed on a Preferred Tier, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 5, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that--following the approval of Janssen Biotech's Stelara for psoriatic arthritis--about one-third of surveyed dermatologists expect to at least...

2013-11-12 23:25:17

Reportbuyer.com just published a new market research report: Psoriasis Treatment: World Drug Market 2013-2023. London (PRWEB) November 12, 2013 Report Details Psoriasis drugs - this new study shows you R&D, opportunities, and potential revenues What's the future of treating psoriasis? Visiongain's new report gives you revenue predictions from 2013, helping you stay ahead. There you see financial results, R&D trends, opportunities, and potential revenues. Avoid falling...

2013-10-28 08:29:21

Integrated Analysis of Two Pivotal Phase 3 Studies Showed STELARA Inhibited the Progression of Structural Damage at Week 24, and Demonstrated Continued Inhibition through Two Years SAN DIEGO, Oct. 28, 2013 /PRNewswire/ -- New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA(® )(ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared...

2013-10-21 08:29:21

People on biologic or systemic drugs should only receive inactivated vaccines PORTLAND, Ore., Oct. 21, 2013 /PRNewswire-USNewswire/ -- National Psoriasis Foundation (NPF) Medical Board recommends that people with psoriasis and psoriatic arthritis only receive inactivated flu vaccines while on drugs that suppress the immune system. People should talk with their doctors about vaccinations before starting immunosuppressive treatments, such as biologic or systemic drugs, the medical board...

2013-10-14 23:21:18

Reportbuyer.com just published a new market research report: PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022. London (PRWEB) October 14, 2013 Summary GlobalData has released its new Country report, “PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective,...

2013-09-23 08:28:09

First and Only Anti-IL-12/23 Treatment Approved for Adult Patients Living with Psoriatic Arthritis HORSHAM, Pa., Sept. 23, 2013 /PRNewswire/ -- Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved STELARA(®) (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis. It is estimated that more than two million people in the U.S. are living with psoriatic...

2013-08-27 23:28:42

Avail is conducting a randomized, Phase 3 study comparing the efficacy and safety of a new psoriasis drug with Etanercept and a placebo in patients with moderate-to-severe moderate-to-severe plaque psoriasis. DeLand, Florida (PRWEB) August 27, 2013 *To see if you qualify for this Psoriasis Clinical Trial in Florida, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. There is no cost to participate, no insurance is required,...

2013-06-27 12:27:46

WORCESTER, Mass., June 27, 2013 /PRNewswire/ -- Advanced Clinical Care, a clinical trial center located in Central Mass, is recruiting patients for two plaque psoriasis clinical trials. Advanced Clinical Care has previously run and completed hundreds of clinical trials, helping many people who suffer from a rheumatic disease. With these trials the researchers intend to gain new knowledge about the two treatment medications for people suffering with plaque psoriasis. Both trials run...